CATALYSTYahoo Finance • 22h ago
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?Yahoo Finance report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
Why XNCR Stock surged +2.09% Today — RQD Quant Desk Flash
$29.82 +2.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $29.88
Xencor Inc. (XNCR) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.22B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on XNCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is XNCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Xencor Inc. (NASDAQ: XNCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $29.82 (+2.09% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XNCR ranks #302 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does XNCR compare to AUPH and VERA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XNCR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.3%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for XNCR?
▼
Per XNCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326732), Xencor Inc. generated $125.6M in revenue (+13.7% YoY), -$91.9M in net income, and -$138.3M in free cash flow against $875.5M in total assets and $76.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $29.88 (+0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XNCR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY XNCR SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (36% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (26% of score)
Altman Z-Score 4.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$23.52+6% Next Q
39
Q2 (-2Q)Grade D$24.94+20.2% Next Q
42
Q3 (-1Q)Grade D$29.99-0.6% Next Q
44
CurrentGrade D$29.82-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a XNCR Turnaround Squeeze
While XNCR currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.78) and Max Pain ($31.31) forces dealer call-delta covering toward $35.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $XNCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XNCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why XNCR Stock surged +2.09% Today — RQD Quant Desk Flash
Xencor Inc. (XNCR) surged +2.09% to $29.82, trading at 84% of its 52-week range ($10.38 – $33.6). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 84% of its 52-week range ($10.38 – $33.6) with RSI-14 at 66.2 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $29.82 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live XNCR Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR)Seeking Alpha report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvestor's Business Daily • 1d ago
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer DataInvestor's Business Daily report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Why Is Xencor Stock Trading Higher Today? - Xencor (NASDAQ:XNCR)Benzinga report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Xencor (Nasdaq:XNCR) - Stock AnalysisSimply Wall St report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A kidney cancer study’s results will be presented in Madrid Oct. 25Stock Titan report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Xencor, Inc. (XNCR) Stock ForecastsYahoo Finance report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Xencor, Inc. (XNCR) - What Are Researchers Saying About This Stock?MarketBeat report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 6d ago
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets SaysXencor's (XNCR) shares have strong upside potential due to "exciting" phase 1 data that exceeded exp
CATALYSTBenzinga • 7d ago
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XNCR)
- ✓Walkthrough of XNCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
XNCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +123.20%▲ ASCENDING CHANNEL
2026-11-03O $29.21H $29.82L $29.21C $29.82VOL 1.29M
RES: $34.02SUP: $23.24SMA50: $25.78SMA200: $17.12
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
XNCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +13.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on XNCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for XNCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XNCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XNCR)
Health Care Rank #302 of 1015
⚔️ AUPH vs XNCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (XNCR vs. AUPH, VERA, PRGO, HRMY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Xencor Inc. (XNCR) ranks #302 by composite RQD confidence (47/100, grade D) and #238 by equity capitalization ($2.22B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with XNCR at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XNCR
ACTIVE
Xencor Inc. | D | 47/100 | — | — | -21.3% | +2.09% | $2.22B | Benchmark Subject |
| AUPH Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.25% | $2.22B | /auph-vs-xncr → |
| VERA Vera Therapeutics Inc. (Class A) | E | 31/100 | — | — | -35.0% | +1.47% | $2.23B | /vera-vs-xncr → |
| PRGO Perrigo Company plc | D | 49/100 | — | 35.1% | -13.6% | -0.75% | $2.19B | /prgo-vs-xncr → |
| HRMY Harmony Biosciences Holdings Inc. | A | 86/100 | 14.2x | 77.2% | 63.0% | +0.44% | $2.26B | /hrmy-vs-xncr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326732 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xencor Inc. (XNCR) reported GAAP revenue of $125.6M (+13.7% vs. FY2024 revenue of $110.5M , and -28.1% cumulative change since FY2023) , GAAP net income of -$91.9M, operating cash flow of -$135.1M, and free cash flow of -$138.3M (+33.6% YoY). On the balance sheet, XNCR closed FY2025 with $875.5M in total assets against $76.5M in total debt (Altman Z-Score: 4.32, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $125.6M | -$91.9M | -$135.1M | -$138.3M | $875.5M | $76.5M |
| FY2024 (FY) | 2024-12-31 | $110.5M | -$232.6M | -$202.2M | -$208.3M | $951.9M | $115.2M |
| FY2023 (FY) | 2023-12-31 | $174.6M | -$133.1M | -$77.9M | -$77.9M | — | — |
3. XNCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XNCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Xencor Inc. (NASDAQ: XNCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $29.82 (+2.09% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XNCR ranks #302 in composite RQD confidence.
How does XNCR compare to AUPH and VERA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XNCR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.3%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XNCR?
Per XNCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326732), Xencor Inc. generated $125.6M in revenue (+13.7% YoY), -$91.9M in net income, and -$138.3M in free cash flow against $875.5M in total assets and $76.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XNCR trading relative to its 50-day, 200-day, and 52-week technical levels?
XNCR last traded at $29.82 (+2.09% on volume of 1,289,685 shares), positioning the stock +15.67% above its 50-day simple moving average ($25.78) and +74.18% above its 200-day simple moving average ($17.12). Across its 52-week range of $10.38 to $33.60, XNCR sits at the 83.7% percentile with a 14-day RSI of 66.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($26.09 to $33.55).
ROARABLE RATING BRIEF • RQD 47/100 (D)
✓ SEC XBRL & RQD VERIFIED
XNCR — Xencor Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Xencor Inc. (XNCR) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $29.82 (+2.09% 1D, market capitalization $2.22B).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -21.3%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -6.37%.
- Whale 13F & Options Flow (17/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.32, Piotroski F-Score of 4/9, and Debt/Equity of 0.12x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Xencor Inc. (XNCR) is listed on NASDAQ and classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $125.6M for FY 2025 .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xencor Inc. (XNCR) reported $125.6M in annual revenue (up from $110.5M in FY2024, +13.7% YoY) and -$91.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($174.6M revenue, -$133.1M net income) through FY2025, XNCR scaled operating cash flow to -$135.1M and free cash flow to -$138.3M, backed by $875.5M in total assets against $76.5M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 47/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -6.37% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $10.38 – $33.60 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream links are mapped, no sector correlations are provided beyond the Health Care classification, and no bottlenecks are identified.
- Key Question #1: Can XNCR sustain or expand its -60.0% operating margin and -21.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $125.6M and free cash flow of -$138.3M, how will capital allocation balance growth reinvestment against $76.5M in total debt?
- Key Question #3: How sensitive is XNCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
XNCR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Xencor Inc. (XNCR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 22h ago
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update? Yahoo Finance report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) Seeking Alpha report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investor's Business Daily • 1d ago
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data Investor's Business Daily report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Why Is Xencor Stock Trading Higher Today? - Xencor (NASDAQ:XNCR) Benzinga report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Xencor (Nasdaq:XNCR) - Stock Analysis Simply Wall St report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A kidney cancer study’s results will be presented in Madrid Oct. 25 Stock Titan report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Xencor, Inc. (XNCR) Stock Forecasts Yahoo Finance report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Xencor, Inc. (XNCR) - What Are Researchers Saying About This Stock? MarketBeat report covering Xencor Inc. (XNCR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
XNCR Bull vs. Bear Conversation Board — What's Your Call at $29.82?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XNCR 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $35.49 (+19.0%)
📌 Pinned Debate Institutional whale 13F flow scores 16 of 20 and the balance sheet shows an Altman Z of 4.32 with debt falling from $115.2M to $76.5M.
Don't sleep on XNCR's setup in Health Care. Institutional whale 13F flow scores 16 of 20 and the balance sheet shows an Altman Z of 4.32 with debt falling from $115.2M to $76.5M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
@MeanReversion_88 Shorting a 17/20 institutional whale-flow stock at $29.82 is dangerous when funds are rotating into Health Care.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $25.05 (-16.0%)
Spot @ $29.82 ROIC of -21.3%, FCF yield of -6.37%, and FY 2025 free cash flow of -$138.3M against $54.1M of cash point to sustained cash burn.
Here is the bear case nobody on the bull side wants to address on XNCR: ROIC of -21.3%, FCF yield of -6.37%, and FY 2025 free cash flow of -$138.3M against $54.1M of cash point to sustained cash burn.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.